Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Include these trace minerals in your diet and supplementation

High-dose GHRP-6: Moderate-high risk Why it's concerning: Significant appetite increase (can derail diet) Prolactin elevation (gynecomastia risk in sensitive individuals) Cortisol increase at high doses Water retention When it might be acceptable: Moderate doses (100-200mcg, not 300+mcg) Short-term use (8-12 weeks) If appetite increase isn't problematic Safer alternatives: Ipamorelin (no prolactin/cortisol increase) Lower GHRP-6 doses with careful monitoring Hexarelin: Higher risk than benefits justify Why it's problematic: Rapid desensitization (must cycle frequently) Cortisol and prolactin elevation Heart stress concerns Diminishing returns Limited use cases: Very short cycles (4 weeks maximum) Experienced users only With careful monitoring Better options: Ipamorelin for sustained results GHRP-2 for middle ground Synthetic growth hormone: Highest overall risk Why avoid: Complete shutdown of natural GH production Organ growth (hands, feet, jaw, internal organs) Insulin resistance Expensive Requires PCT (post-cycle therapy) Legal issues in most countries Only justified for: Medical growth hormone deficiency Under physician supervision Replacement doses, not supraphysiological Much safer alternatives: CJC-1295 + Ipamorelin stack Natural peptides that stimulate endogenous GH No shutdown, no PCT needed See peptides vs steroids and peptides vs SARMs for safety comparisons

Is there a money-back guarantee
Melanocortin 4 receptor agonist An melanocortin 4 receptor (MC4R) agonist, a synthetic peptide, binds to human MC4R, leading to decreased food intake and substantial weight loss [4]